Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen as Adjunct to HAART in HIV
NCT00035581Phase 2Terminated
- Sponsor
- AIM ImmunoTech
- Start
- May 2001
- Primary completion
- Sep 2005
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rintatolimod in human immunodeficiency virus infection (HIV) (2 arms), sponsored by AIM ImmunoTech. Primary endpoint: Reduction in HIV-1 Viral Load at 24 weeks. Started May 2001; status: terminated.
02
Drugs
rintatolimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00035581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035581.